<DOC>
	<DOCNO>NCT01254773</DOCNO>
	<brief_summary>This study individual mild moderate Alzheimer 's Disease design ass : ( 1 ) safety tolerability ( 2 ) capacity subcutaneous bapineuzumab reduce brain amyloid load measure positron emission tomography ( PET ) scan .</brief_summary>
	<brief_title>Amyloid Imaging And Safety Study Of Subcutaneous Bapineuzumab In Subjects With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis probable AD Age 50 less 89 MiniMental Status Exam score 1826 inclusive Brain magnetic resonance imaging ( MRI ) scan consistent diagnosis AD Stable dose medication ( cholinesterase inhibitor memantine allow ) Caregiver able attend clinic visit patient Amyloid burden screen PET scan consistent diagnosis AD Significant neurological disease AD Major psychiatric disorder Significant systemic illness History stroke seizure , autoimmune disease , myocardial infarction within last 2 year Smoking great 20 cigarette per day Anticonvulsants , antiParkinson 's , anticoagulant , narcotic medication Prior treatment experimental immunotherapeutics vaccine AD Women childbearing potential Presence pacemaker , CSF shunt , foreign metal object eye , skin body</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>